Evidence map›Paper›PMID 27683847›Full record

ArticleNeurology2016

Cognitive reserve in frontotemporal degeneration: Neuroanatomic and neuropsychological evidence.

Katerina Placek, Lauren Massimo, Christopher Olm, Kylie Ternes, Kim Firn, Vivianna Van Deerlin, Edward B Lee, John Q Trojanowski, Virginia M-Y Lee, David Irwin and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Cognitive reserve in individuals with frontotemporal dementia: a systematic review.Journal of clinical and experimental neuropsychology · 2024
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Cognitive reserve in ALS: the role of occupational skills and requirements.Amyotrophic lateral sclerosis & frontotemporal degeneration · 2024
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Katerina PlacekFrom the Department of Neurology, Penn Frontotemporal Degeneration Center (K.P., L.M., C.O., K.T., K.F., D.I., M.G., C.T.M.), and Department of Pathology & Laboratory Medicine, Center for Neurodegenerative Disease Research (V.V.D., E.B.L., J.Q.T., V.M.-Y.L., D.I.), University of Pennsylvania, Philadelphia.
Lauren MassimoFrom the Department of Neurology, Penn Frontotemporal Degeneration Center (K.P., L.M., C.O., K.T., K.F., D.I., M.G., C.T.M.), and Department of Pathology & Laboratory Medicine, Center for Neurodegenerative Disease Research (V.V.D., E.B.L., J.Q.T., V.M.-Y.L., D.I.), University of Pennsylvania, Philadelphia.
Christopher OlmFrom the Department of Neurology, Penn Frontotemporal Degeneration Center (K.P., L.M., C.O., K.T., K.F., D.I., M.G., C.T.M.), and Department of Pathology & Laboratory Medicine, Center for Neurodegenerative Disease Research (V.V.D., E.B.L., J.Q.T., V.M.-Y.L., D.I.), University of Pennsylvania, Philadelphia.
Kylie TernesFrom the Department of Neurology, Penn Frontotemporal Degeneration Center (K.P., L.M., C.O., K.T., K.F., D.I., M.G., C.T.M.), and Department of Pathology & Laboratory Medicine, Center for Neurodegenerative Disease Research (V.V.D., E.B.L., J.Q.T., V.M.-Y.L., D.I.), University of Pennsylvania, Philadelphia.
Kim FirnFrom the Department of Neurology, Penn Frontotemporal Degeneration Center (K.P., L.M., C.O., K.T., K.F., D.I., M.G., C.T.M.), and Department of Pathology & Laboratory Medicine, Center for Neurodegenerative Disease Research (V.V.D., E.B.L., J.Q.T., V.M.-Y.L., D.I.), University of Pennsylvania, Philadelphia.
Vivianna Van DeerlinFrom the Department of Neurology, Penn Frontotemporal Degeneration Center (K.P., L.M., C.O., K.T., K.F., D.I., M.G., C.T.M.), and Department of Pathology & Laboratory Medicine, Center for Neurodegenerative Disease Research (V.V.D., E.B.L., J.Q.T., V.M.-Y.L., D.I.), University of Pennsylvania, Philadelphia.
Edward B LeeFrom the Department of Neurology, Penn Frontotemporal Degeneration Center (K.P., L.M., C.O., K.T., K.F., D.I., M.G., C.T.M.), and Department of Pathology & Laboratory Medicine, Center for Neurodegenerative Disease Research (V.V.D., E.B.L., J.Q.T., V.M.-Y.L., D.I.), University of Pennsylvania, Philadelphia.
John Q TrojanowskiFrom the Department of Neurology, Penn Frontotemporal Degeneration Center (K.P., L.M., C.O., K.T., K.F., D.I., M.G., C.T.M.), and Department of Pathology & Laboratory Medicine, Center for Neurodegenerative Disease Research (V.V.D., E.B.L., J.Q.T., V.M.-Y.L., D.I.), University of Pennsylvania, Philadelphia.
Virginia M-Y LeeFrom the Department of Neurology, Penn Frontotemporal Degeneration Center (K.P., L.M., C.O., K.T., K.F., D.I., M.G., C.T.M.), and Department of Pathology & Laboratory Medicine, Center for Neurodegenerative Disease Research (V.V.D., E.B.L., J.Q.T., V.M.-Y.L., D.I.), University of Pennsylvania, Philadelphia.
David IrwinFrom the Department of Neurology, Penn Frontotemporal Degeneration Center (K.P., L.M., C.O., K.T., K.F., D.I., M.G., C.T.M.), and Department of Pathology & Laboratory Medicine, Center for Neurodegenerative Disease Research (V.V.D., E.B.L., J.Q.T., V.M.-Y.L., D.I.), University of Pennsylvania, Philadelphia.
Murray GrossmanFrom the Department of Neurology, Penn Frontotemporal Degeneration Center (K.P., L.M., C.O., K.T., K.F., D.I., M.G., C.T.M.), and Department of Pathology & Laboratory Medicine, Center for Neurodegenerative Disease Research (V.V.D., E.B.L., J.Q.T., V.M.-Y.L., D.I.), University of Pennsylvania, Philadelphia.
Corey T McMillanFrom the Department of Neurology, Penn Frontotemporal Degeneration Center (K.P., L.M., C.O., K.T., K.F., D.I., M.G., C.T.M.), and Department of Pathology & Laboratory Medicine, Center for Neurodegenerative Disease Research (V.V.D., E.B.L., J.Q.T., V.M.-Y.L., D.I.), University of Pennsylvania, Philadelphia. mcmillac@upenn.edu.
Pennsylvania Academic Library Consortium · US

Funding

Transgenic Mouse Models of Tau PathologiesP01AG017586 · NIA · UNIVERSITY OF PENNSYLVANIA · PI LEE, VIRGINIA M · 2000 to 2021
$37.3M
UPenn ADCC Biomarker CoreP30AG010124 · NIA · UNIVERSITY OF PENNSYLVANIA · PI XIE, SHARON XIANGWEN · 1991 to 2020
$35.1M
Neural Basis of Generalized QuantifiersR01NS044266 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI GROSSMAN, MURRAY · 2004 to 2014
$6.8M
TDP-43 Proteinopathies in ALS-DementiaP01AG032953 · NIA · UNIVERSITY OF PENNSYLVANIA · PI LEE, VIRGINIA M · 2010 to 2014
$5.8M
Multimodal Biomarkers in Frontotemporal Lobar DegenerationK01AG043503 · NIA · UNIVERSITY OF PENNSYLVANIA · PI MCMILLAN, COREY T · 2013 to 2017
$642k
The Neural Basis of Apathy in Frontotemporal Degeneration: A Longitudinal StudyF32NR014777 · NINR · PENNSYLVANIA STATE UNIVERSITY, THE · PI MASSIMO, LAUREN M · 2013 to 2016
$144k
NIA NIH HHS K01 AG043503NIA NIH HHS P01 AG017586NIA NIH HHS P01 AG032953NIA NIH HHS P30 AG010124NINDS NIH HHS R01 NS044266NINR NIH HHS F32 NR014777
6 · The paper itself

Abstract

objectiveTo evaluate if cognitive reserve (CR) contributes to interindividual differences in frontal gray matter density (GMD) and executive impairment that underlie heterogeneity in the disease course of confirmed frontotemporal lobar degeneration (FTLD) pathology.

methodsFifty-five patients with autopsy confirmation or a pathogenic mutation consistent with underlying tau (FTLD-tau) or TDP-43 (FTLD-TDP) pathology and 90 demographically comparable healthy controls were assessed with T1 MRI and neuropsychological measures (Mini-Mental State Examination, letter fluency, forward digit span, Rey complex figure, and Boston Naming Test). CR was indexed using a composite measure of education and occupation. We used t tests to identify reduced GMD in patients with FTLD relative to controls, regression analyses to relate reduced GMD to CR index, and correlations to relate regions of GMD associated with CR to performance on neuropsychological measures.

resultsPatients with FTLD demonstrated impairment on neuropsychological measures. Patients with FTLD exhibited reduced bilateral frontotemporal GMD relative to controls, consistent with the known anatomic distribution of FTLD pathology. Higher CR index was associated with superior letter fluency and with GMD in right dorsolateral prefrontal cortex, orbitofrontal cortex, rostral frontal cortex, and inferior frontal gyrus. Furthermore, we found that higher GMD in frontal regions associated with CR was associated with superior letter fluency.

conclusionsExecutive control and verbal ability assessed by letter fluency in FTLD is mediated in part by CR and frontal GMD. The identification of factors influencing cognitive and anatomic heterogeneity in FTLD suggests that CR should be considered in symptom detection, prognosis, and treatment.

Indexed as

AgedCognition DisordersCognitive ReserveFemaleFrontotemporal Lobar DegenerationGray MatterHumansImage Processing, Computer-AssistedMagnetic Resonance ImagingMaleMiddle AgedNeuropsychological Tests

Identifiers

PMID27683847
PMCPMC5089523
OpenAlexW2525330944

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.